Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03533751 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by AnaptysBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
NCT03533751 is a Phase 2 study that has completed, run by AnaptysBio. The registered enrollment target is 302 participants.
The verdict
NCT03533751, a Phase 2 study, has completed, sponsored by AnaptysBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
Interventions
- DRUG Placebo
- BIOLOGICAL Etokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2019-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03533751
The ClinicalTrials.gov registry entry for NCT03533751 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AnaptysBio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03533751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03533751 about?
NCT03533751 is a clinical study titled "Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis". This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).
What is the current status of trial NCT03533751?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2018-06-19. Estimated completion is 2019-12-03.
What interventions are being tested in trial NCT03533751?
The interventions under investigation include: Placebo (DRUG), Etokimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03533751?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.